Federated Hermes’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$22.3M Buy
129,340
+3,500
+3% +$649K 0.04% 445
2025
Q4
$25.1M Sell
125,840
-386
-0.3% -$70K 0.04% 402
2025
Q3
$19.7M Buy
126,226
+160
+0.1% +$25.4K 0.03% 433
2025
Q2
$19.1M Buy
126,066
+125,841
+55,929% +$16.8M 0.04% 440
2025
Q1
$33.9K Sell
225
-2,172
-91% -$364K ﹤0.01% 1671
2024
Q4
$442K Sell
2,397
-42,039
-95% -$8.1M ﹤0.01% 1348
2024
Q3
$8.75M Sell
44,436
-4,704
-10% -$978K 0.02% 605
2024
Q2
$10.2M Sell
49,140
-39
-0.1% -$8.84K 0.02% 552
2024
Q1
$13.3M Sell
49,179
-25,028
-34% -$5.98M 0.03% 508
2023
Q4
$17.5M Sell
74,207
-99
-0.1% -$19.5K 0.04% 422
2023
Q3
$14.6M Sell
74,306
-30,066
-29% -$6.17M 0.04% 444
2023
Q2
$21.9M Sell
104,372
-22,423
-18% -$4.46M 0.05% 358
2023
Q1
$25.6M Sell
126,795
-23,233
-15% -$5.27M 0.06% 323
2022
Q4
$32.7M Sell
150,028
-36,889
-20% -$8.06M 0.09% 280
2022
Q3
$36.8M Sell
186,917
-25,951
-12% -$5.6M 0.11% 235
2022
Q2
$45.5M Buy
212,868
+18,196
+9% +$4.45M 0.12% 213
2022
Q1
$55.3M Sell
194,672
-19,988
-9% -$6.16M 0.12% 212
2021
Q4
$80.9M Buy
214,660
+15,076
+8% +$5.86M 0.15% 190
2021
Q3
$82.4M Buy
199,584
+4,811
+2% +$2M 0.16% 182
2021
Q2
$72.1M Sell
194,773
-9,689
-5% -$3.24M 0.13% 208
2021
Q1
$59.3M Buy
204,462
+29,137
+17% +$8.1M 0.11% 231
2020
Q4
$43.8M Sell
175,325
-22,415
-11% -$5.34M 0.09% 280
2020
Q3
$44.8M Sell
197,740
-15,033
-7% -$3.12M 0.11% 229
2020
Q2
$37.1M Sell
212,773
-9,295
-4% -$1.48M 0.09% 256
2020
Q1
$28M Buy
222,068
+48,441
+28% +$7.27M 0.08% 264
2019
Q4
$26.5M Buy
173,627
+24,067
+16% +$3.33M 0.06% 335
2019
Q3
$19.8M Buy
149,560
+30,931
+26% +$4.15M 0.05% 373
2019
Q2
$16.8M Buy
118,629
+10,208
+9% +$1.38M 0.04% 395
2019
Q1
$15.7M Buy
108,421
+74,915
+224% +$9.84M 0.04% 412
2018
Q4
$3.79M Buy
33,506
+15,670
+88% +$1.96M 0.01% 816
2018
Q3
$2.4M Sell
17,836
-4,247
-19% -$524K 0.01% 1026
2018
Q2
$2.48M Buy
22,083
+3,537
+19% +$382K 0.01% 928
2018
Q1
$1.98M Sell
18,546
-5,220
-22% -$563K 0.01% 963
2017
Q4
$2.6M Sell
23,766
-4,236
-15% -$461K 0.01% 832
2017
Q3
$3.02M Sell
28,002
-66,585
-70% -$6.84M 0.01% 743
2017
Q2
$9.57M Buy
94,587
+69,352
+275% +$6.38M 0.03% 412
2017
Q1
$2.27M Sell
25,235
-1,238
-5% -$105K 0.01% 858
2016
Q4
$2.02M Sell
26,473
-48,884
-65% -$3.71M 0.01% 862
2016
Q3
$6.28M Sell
75,357
-48,628
-39% -$4.08M 0.02% 515
2016
Q2
$10.2M Sell
123,985
-3,146
-2% -$259K 0.03% 425
2016
Q1
$9.65M Buy
127,131
+68,413
+117% +$5.06M 0.03% 418
2015
Q4
$4.72M Buy
58,718
+32,741
+126% +$2.36M 0.01% 581
2015
Q3
$1.65M Sell
25,977
-2,165
-8% -$155K 0.01% 936
2015
Q2
$1.98M Sell
28,142
-430
-2% -$31.8K 0.01% 926
2015
Q1
$2.27M Buy
28,572
+1,312
+5% +$96.8K 0.01% 920
2014
Q4
$1.73M Sell
27,260
-11,053
-29% -$693K 0.01% 1009
2014
Q3
$2.29M Sell
38,313
-2,070
-5% -$118K 0.01% 911
2014
Q2
$2.16M Buy
40,383
+9,066
+29% +$497K 0.01% 929
2014
Q1
$1.89M Sell
31,317
-574
-2% -$33.5K 0.01% 973
2013
Q4
$1.69M Sell
31,891
-3,489
-10% -$175K 0.01% 994
2013
Q3
$1.64M Buy
35,380
+5,254
+17% +$241K 0.01% 977
2013
Q2
$1.24M Buy
+30,126
New +$1.29M ﹤0.01% 1050

Other funds holding CRL

Federated Hermes's CRL Position: Q1 2026 in Review

Federated Hermes increased its Charles River Laboratories (CRL) stake by 2.8% in Q1 2026, buying an estimated $649K and bringing the position to 129,340 shares worth $22.3M. The position accounts for 0.04% of the portfolio, ranked #445.

Federated Hermes first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. The position peaked at $82.4M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Federated Hermes held 129,340 shares of Charles River Laboratories worth $22.3M as of Q1 2026.
  • Federated Hermes bought 3,500 Charles River Laboratories shares in Q1 2026, an estimated $649K.
  • Charles River Laboratories made up 0.04% of Federated Hermes's portfolio in Q1 2026, its #445 holding.
  • Federated Hermes first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
  • Federated Hermes's Charles River Laboratories position peaked at $82.4M in Q3 2021.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.